|Bid||116.01 x 800|
|Ask||119.49 x 900|
|Day's Range||116.80 - 119.05|
|52 Week Range||72.13 - 120.53|
|Beta (5Y Monthly)||0.74|
|PE Ratio (TTM)||52.21|
|Earnings Date||May 27, 2021|
|Forward Dividend & Yield||2.32 (1.97%)|
|Ex-Dividend Date||Dec 21, 2020|
|1y Target Est||133.54|
Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
The latest back-to-back incidents will, undoubtedly, create a major drag in Medtronic's (MDT) VAD performance.